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ABSTRACT: Vaccines based on isolated polysaccharides success-
fully protect humans from bacterial pathogens such as Streptococcus
pneumoniae. Because polysaccharide production and isolation can
be technically challenging, glycoconjugates containing synthetic
antigens are an attractive alternative. Typically, the shortest
possible oligosaccharide antigen is preferable as syntheses of
longer structures are more difficult and time-consuming.
Combining several protective epitopes or polysaccharide repeating
units as blocks by bonds other than glycosidic linkages would
greatly reduce the synthetic effort if the immunological response to
the polysaccharide could be retained. To explore this concept, we
bridged the well-understood and immunologically potent RU of S.
pneumoniae serotype 14 (ST14) with an aliphatic spacer and conjugated it to the carrier protein CRM197. Mice immunized with the
spacer-bridged glycan conjugates produced high levels of specific antibodies after just one or two vaccine doses, while the
tetrasaccharide repeating unit alone required three doses. The antibodies recognized specifically ST14 CPS, while no significant
antibody levels were raised against the spacer or unrelated CPS. Synthetic vaccines generated antibodies with opsonic activity.
Mimicking polysaccharides by coupling repeating unit antigens via an aliphatic spacer may prove useful also for the development of
other glycoconjugate vaccine candidates, thereby reducing the synthetic complexity while enhancing a faster immune response.
Bacterial capsular polysaccharides (CPS) comprised ofrepeating units have been identified as major virulence
factors of bacterial pathogens.1 Polysaccharide and glyco-
conjugate vaccines based on isolated CPS induce a protective
immune response in people and prevent millions of deaths
every year caused by pathogenic bacteria such as Streptococcus
pneumoniae.2 Almost all currently marketed vaccines rely on
CPS isolated from bacterial culture. The isolation and
purification of CPS from pathogens in sufficient quantities3,4
can be challenging as other cellular polysaccharides are
frequently found in CPS preparations even though their
implications on the human immune system are not known.
Certain CPS degrade during isolation or formulation, thus
rendering the vaccine ineffective.5−8 Semisynthetic glycocon-
jugate vaccines,9,10 containing a synthetic oligosaccharide
antigen resembling the CPS coupled to a carrier protein,
have emerged as an attractive option with great potential for
understanding glycan immunology and rationally designing
efficacious bacterial vaccines.
A key consideration during synthetic vaccine design is
antigen length. While CPS are many hundreds or thousands of
monosaccharides in length, a majority of CPS repeating units
vary fom two to six monosaccharides. Usually, just one or two
synthetic repeating units are suffient to induce a protective
immune response.11 To produce specific antibodies against the
CPS, B cells need to be activated and differentiated after
binding to the glycoconjugate. The process relies primarily on
B cell receptors (BCR) to sense the foreign antigen triggering a
molecular cascade turning naiv̈e B cells into mature antigen-
specific B cells.12 Numerous studies have shown that
multivalent antigens are more efficient than monovalent
antigens in promoting an antibody response, mainly because
it induces BCR clustering leading to greater signal activation
and consequently B cell differentiation.13−16 Thus, earlier and
stronger immune response improvement is crucial mainly
when targeting newborns and infants.
Given the challenges associated with the synthesis of
oligosaccharide antigens of increasing length, identifying
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minimal oligosaccharide epitopes is important. It remains to be
seen whether an oligosaccharide chimera consisting of
oligosaccharide repeating units connected via simple spacers
is sufficient to induce a strong immune response associated
with the specific response to polysaccharides. To address this
question at the conceptual level, we focused on the capsular
polysaccharide of S. pneumoniae serotype 14 (ST14). S.
pneumoniae are Gram-positive bacteria that cause severe
invasive pneumococcal diseases (IPDs) such as pneumonia,
septicemia, meningitis, and otitis media.17−20 ST14 is the most
common of the more than 95 serotypes in the human
population21 and accounts for ≤29% of IPDs in children
worldwide.22 The ST14 CPS consists of tetrasaccharide [β-D-
Galp-(1→4)-][→6)β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-β-
D-Glcp-(1→] repeating unit23 that is the minimal structure
required to induce ST14-specific antibodies.24−26
Figure 1. Molecular dynamcs simulations of the ST14 polysaccharide and ST14 polysaccharide mimic. (A and B) Simulation snapshots of the
divalent ST14 mimic and a three-repeat unit ST14 polysaccharide, respectively. Comparison of the distance distributions from 1μs of simulation
data for the distance between O2 and O3 corresponding to the effective linker lenght (C) and the radius of gyration (D). A complete set of the
distance distributions between highlighted oxigen atoms (O1-O4) are shown in the Supporting Information.
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To design a polysaccharide mimic consisting of two ST14
tetrasaccharide repeating units (RU) connected by a linker,
molecular dynamics (MD) simulations27,28 were employed to
sample the conformational space of an oligosaccharide
consisting of three ST14 RUs (Figure 1B). On the basis of
that model, a linker was designed such that the resulting
chimeric structure where the middle RU is replaced by the
spacer corresponds approximately to that of the native glycan
(Figure 1A). To assess the structural similarity between the
synthetic ST14 mimic and the native glycan, the conforma-
tional ensembles of the two molecules were compared using
all-atom MD simulations.
On the basis of this design, just one tetrasaccharide instead
of a dodecasaccharide has to be synthesized and is conjugated
to another unit (Figure 2). The spacer-bridged oligosaccharide
derivatives were designed for conjugation to carrier protein
CRM197 and in vivo immunological assessment. With proper
spacing, the repeating units will interact with B cell receptors
and result in a robust immune response.
■ RESULTS AND DISCUSSION
Hybrid Design by Molecular Modeling. The ST14
dodecasaccharide consisting of three ST14 tetrasaccharide RUs
was modeled with all-atom MD using the GLYCAMOSMO,14
force field.27,28 In designing a linker/spacer to bridge the
middle tetrasaccharide RU, we adopted a two-stage process. A
flexible and immunologically silent linker was envisioned that
would carry minimal functional groups but could be installed
in one simple synthetic manipulation. Amide bond formation
connecting two alkyl linkers was selected for an initial quick
assessment using MacroModel 8.029 that identified the union
of a pentenyl amine and a butanoic acid as a potential solution
for the linker challenge at hand. The polysaccharide mimic was
simulated with MD, using parameters from the Amber SB99
force field30,31 and partial charges derived using the R.E.D.
tools scripts32 for the linker residue. On the basis of these
simulations, the linker segment introduced in the ST14 mimic
is much more flexible than the central tetrasaccharide it
replaces, allowing the molecule to sample a greater conforma-
tional space, as reflected in the wider probability distributions
for the distances shown in panels C and D of Figure 1 (for a
more detailed description, see the Supporting Information).
The synthetic molecule reaches both more compact and more
extended conformations than the comparatively rigid poly-
saccharide, and a significant overlap between the distributions
for the two molecules remains. In addition, the conformational
states within one tetrasaccharide repeat unit remain identical
between the two molecules. Thus, the two saccharides in the
ST14 mimic frequently access conformations that are very
similar to those in the polysaccharide.
Synthetic Strategy. The synthesis of ST14 repeating unit
oligosaccharides (1−3) with linkers at the reducing and
nonreducing ends was based on key ST14 repeating unit
tetrasaccharide 4 (Scheme 1). Tetrasaccharide antigen 4
containing two linkers was assembled by the linear
combination of linker 5, as well as building blocks 6,33 7,
8,34 and 9. Tetrasaccharide 10 that lacks the linker at the
nonreducing end was prepared the same way using building
block 1135 instead of 9.
Oligosaccharide Assembly. Glucosamine building block
6, glucosyl 8, and galactosyl 11 were synthesized by following
the reported procedures.33−35 The synthesis of both galactosyl
Figure 2. (A) Structure of the ST14 capsular polysaccharide. (B) Spacer-bridged ST14 oligosaccharide mimic of the capsular polysaccharide.
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building blocks 7 and 9 commenced with ethyl 4,6-O-
benzylidene-1-thio-β-D-galactopyranoside (see Scheme S1).
With four building blocks in hand, the stage was set to access
tetrasaccharide 4. The protected amino linker was introduced
at the reducing end by glycosylation of 5 and thioglycoside 6
promoted by N-iodosuccinimide (NIS) in the presence of
triflic acid (TfOH), affording 12. Removal of the temporary
fluorenylmethyloxycarbonyl (Fmoc) protecting group gave
compound 13, which was further reacted with galactose 7, thus
yielding the fully protected disaccharide 14. Cleavage of
levulinoyl (Lev) ester with hydrazine hydrate yielded 15 as an
acceptor that was glycosylated with building block 8 to furnish
trisaccharide 16. Cleavage of the Fmoc group followed by
coupling with thioglycoside 9 produced tetrasaccharide 4
(Scheme 2A).
Tetrasaccharide 18 was prepared by glycosylation of
trisaccharide 17 and galactose building block 11 activated
with NIS/TfOH. Removal of Fmoc, benzoyl, and benzyl
protecting groups yielded fully deprotected tetrasaccharide 10
(Scheme 2B).
The methyl ester at the nonreducing end of 4 was cleaved
with a sodium hydroxide solution followed by addition of
excessive sodium methoxide to remove all benzoyl esters,
yielding compound 21. Subsequent hydrogenolysis catalyzed
by palladium on carbon produced tetrasaccharide 1 (Scheme
3A).
Hydrogenation of tetrasaccharide 4 with palladium on
carbon yielded compound 22 that contains a free amino group
at the reducing end. Amide bond formation to couple 21 and
22 proceeded well with benzotriazol-1-yl-oxytripyrrolidino-
phosphonium hexafluorophosphate (PyBOP) and N,N-diiso-
propylethylamine (DIPEA) as 80% spacer-bridged divalent
ST14 antigen 23 was produced (Scheme 3B). 1-[Bis-
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxide hexafluorophosphate36 (HATU) also
successfully catalyzed the coupling but produced some
unidentified byproducts. Removal of all of the ester and
ether protecting groups of 23 using the same procedure that
was used for compound 4 yielded deprotected divalent ST14
2, containing 2 RU. Spacer-bridged trivalent ST14 3 was
Scheme 1. Retrosynthetic Analysis of Capsular Oligosaccharide Derivatives 1−3 and 10
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prepared by PyBOP-mediated coupling of 22 and 24 to afford
25 followed by global deprotection.
A spacer dummy conjugate BSA-35 was synthesized as a
control to detect antibodies against the spacer (Scheme 4).
The synthesis of 35 commenced with phenyl 2-azido-2-deoxy-
4,6-O-benzylidene-1-seleno-α-D-galactopyranoside 27, where
the 5-methoxy-5-oxopentyl group was installed at position
C3 to give 28 that was treated with NIS in the presence of
water followed by 2,2,2-trifluoro-N-phenylacetimidoyl chloride
and cesium carbonate to afford imidate 29. Glycosylation of
linker 5 with 29 produced 30 before the resident azide was
converted into an acetamino group with thioacetic acid in
pyridine. Methyl ester 31 was hydrolyzed to yield 32 with a
free carboxyl group, while hydrogenation resulted in 33
containing an amino group. Coupling of 32 and 33 with
PyBOP furnished 34 that was fully deprotected to give 35. The
conjugation of 35 and BSA was achieved using bifunctional p-
nitrophenyladipate (Scheme 4B) and characterized via
MALDI-TOF (see Figure S3).
Human Anti-ST14 CPS Antibodies Bind Synthetic
Glycans. Synthetic glycans 1−3 and 10 and native CPS14
were covalently immobilized on glass slides (Figure 3A). A
spacer dummy conjugate BSA-35 was used as a control to
detect antibodies against the spacer. After incubation with a
human reference serum of patients vaccinated with a CPS-
based vaccine, the bound antibodies were detected using
fluorescently labeled secondary anti-human antibodies. The
human serum contained antibodies that bound all synthetic
glycan derivatives 1−3. Spacer 35 was not significantly bound
by antibodies present in human sera (Figure 3B).
Preparation and Characterization of Glycoconju-
gates. The synthetic ST14-related glycans 1−3 and 10 were
conjugated to carrier protein CRM197 using the homobifunc-
tional reagent, adipate 4-nitro phenyl diester,37 under mild
conditions (Figure 4A). Coupling of 0.1 μmol of oligossac-
charide to 1 mg of CRM197 resulted in glycoconjugates
containing 10 (1), 11 (2), 7 (3), and 10 (10) glycans per
molecule of CRM197. The loading was calculated by matrix-
assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF MS) and confirmed by sodium
dodecyl sulfate−polyacrylamide gel electrophoresis (see Figure
S2).
Evaluation of the Immunogenicity of Glycoconju-
gates. Mice were immunized with the semisynthetic
glycoconjugates to determine the immunogenicity of the
synthetic ST14 glycans using aluminum hydroxide that is
approved for human use as an adjuvant.38 Immunizations with
the vaccine formulation started on day 0, followed by a boost
on days 14 and 28 (Figure 4B). Mice immunized with
synthetic glycans produced specific antibodies against ST14
CPS. Interestingly, the antibody levels of mice immunized with
ST14 glycans 3 were significantly higher than those with
tetrasaccharide 10 already on day 14 (p < 0.05), while the
levels of constructs 1 and 2 were significantly higher (p <
0.001) after the first boost (day 21) when compared to those
with the synthetic tetrasaccharide 10 (Figure 4C). Overall, the
Scheme 2. Synthesis of Tetrasaccharides 4 and 10
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trivalent derivative CRM197-3 group showed an antibody titer
higher than that of the tetrasaccharide CRM197-10 group (p <
0.001) on days 14 and 35, supporting the concept that the
increase in antigen length may lead to better BCR activation,
eliciting better antibody production.13
Antibodies Raised against Synthetic Glycans Recog-
nize the Specific Epitope of ST14 CPS. To test the specifity
of binding of the antibody to ST14 CPS, mice sera from each
group were incubated with the native capsular polysaccharide
of serotype 2 and 14 and synthetic glycans on a microarray.
Antibodies from individual mouse sera from each group
recognized the synthetic structures of 1−3 and 10 and ST14
CPS, while no significant cross-reactivity was detected against
ST2 CPS or the spacer. Antibodies that were produced
following vaccinations with synthetic glycans were found to be
specific to ST14 CPS (Figure 5B).
Antibodies Raised against Synthetic Glycans Show
Opsonophagocytic Killling Activity In Vitro. Protective
immunity against S. pneumoniae is mainly antibody-mediated.39
To prove the functional activity of antibodies raised against
synthetic glycans, we performed an opsophagocytic killing
assay (OPKA) in vitro. Pooled sera of mice immunized with
CRM197-10, CRM197-1, CRM197-2, CRM197-3, or PBS
with aluminum hydroxide after three doses (Figure 6A) were
incubated with HL-60 cells, baby rabbit complement, and
ST14 bacteria. The human anti-pneumococcal reference serum
Scheme 3. Synthesis of Oligosaccharide Derivatives 1−3
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(007sp) was used as a standard reference.40 The antibodies
raised against synthetic antigens showed very similar
antibacterial activity of 007sp, while sera from the PBS group
showed no antibacterial activity (Figure 6B). A four-parameter
Scheme 4. (A) Synthesis of spacer 35 and (B) Conjugation of 35 to BSA
Figure 3. Native and synthetic oligosaccharides immobilized on a glycan microarray were incubated with the human reference serum of patients
immunized with S. pneumoniae CPS. (A) Microarray in which glycans 1−3 and 10 were immobilized were bound by human IgG antibodies. (B)
IgG antibody binding to synthetic glycans. No significant binding was detected against the spacer (BSA-35). A serum dilution of 1:100 was used in
the analysis. Abbreviations: MFI, mean fluorescence intensity (mean ± standard deviation); PB, printing buffer; CPS, capsular polysaccharide;
CWPS, cell wall polysaccharide; BSA, bovine serum albumin.
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Figure 4. Antibody levels of mice immunized with glycoconjugates. (A) Preparation of conjugates. (B) Immunization schedule. Mice were
immunized on day 0 followed by two boosts on days 14 and 28. Blood was collected at each time point. (C) IgG antibody levels of mice
immunized with synthetic glycans were measured using ELISA plates coated with CPS of S. pneumoniae serotype 14. Glycoconjugate CRM197-3
induced significantly higher antibody levels on day 14 and glycoconjugates CRM197-1 and CRM197-2 after the first boost (day 21) when
compared to those of tetrasaccharide glycoconjugate CRM197-10, which increased markedly only after the second boost. Overall, CRM197-3
showed significantly higher antibody titer when compared to that of tetrasaccharide CRM197-10. The 1:100 serum dilution was used in the
analysis. Abbreviations: A.U., absorbance units; PBS, phosphate-buffered saline. ***p < 0.001. **p < 0.01. *p < 0.05 (mean ± standard deviation).
Figure 5. Glycan microarray incubated with sera of mice immunized with synthetic glycans conjugated to CRM197 and formulated with aluminum
hydroxide. (A) Mice produced specific antibodies against native capsular polysaccharide CPS 14, synthetic glycan 10, and oligosaccharide
derivatives 1−3. No significant binding to CPS 2 or spacer BSA-35 was detected. (B) The divalent and trivalent derivative glycans showed the
highest level of binding throughout the groups. A serum dilution of 1:100 was used in the analysis. Abbreviations: MFI, mean fluorescence
intensity; PBS, phosphate-buffered saline.
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logistic model was applied to establish the serum dilution point
at which 50% of the bacteria are killed (opsonic index). The
results are in the range of the accepted confidence interval of
reference serum,40 and the opsonic indices of 007sp serum,
CRM197-10, CRM197-1, CRM197-2, and CRM197-3 were in
a very similar range (Figure 6C). These results are expected
because the tetrasacchairde RU alone has already been proven
to elicit antibodies with opsonic activity.24 The combination of
two or three RU with a spacer should not change the antibody
activity because the tetrasaccharide RU remains the same.
Thus, the sequential linkage of ST14 RU does not affect the
opsonic activity of generated antibodies against ST14.
■ SIGNIFICANCE
Mono-, di-, and trivalent ST14 derivatives 1−3, respectively,
were rapidly synthesized by bridging RUs with an aliphatic 10-
carbon spacer. The ST14 oligosaccharide derivatives were
conjugated with carrier protein CRM197 to form semi-
synthetic neo-glycoconjugates. These neoglycoconjugates
were formulated with aluminum hydroxide and immunologi-
cally evaluated in mice. Both glycan array and ELISA analyses
of the immune sera demonstrated that the aliphatic spacer
decreased neither antigenicity nor immunogenicity. Interest-
ingly, the ST14-specific antibody responses against derivatives
1−3 were significantly higher after only one or two
immunizations when compared to that of the branched
tetrasaccharide RU only. Most importantly, the sequential
linkage of ST14 repeating units does not impair the opsonic
killing activity of generated antibodies.
The strategy of spacing synthetic repeating unit glycan
antigens with linkers of the appropriate length to mimic
capsular polysaccharides is promising for the design of
semisynthetic glycoconjugate vaccine candidates and results
in a faster, specific antibody response. Higher antibody levels
holding opsonic activity in the earlier immunization phase are
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